Pyoderma gangrenosum: pathogenetic mechanisms and their implications for treatment

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Pyoderma gangrenosum (PG) is a rare, inflammatory skin disease.
• Its pathogenesis involves genetic predisposition and immune dysregulation, leading to neutrophil-driven damage.
• Current treatments include immunosuppressants, immunomodulatory drugs, topical therapies, and wound management.

Purpose of the Study:

• To review established and emerging treatments for pyoderma gangrenosum.
• To discuss pathogenesis-driven therapeutic strategies.
• To provide a therapeutic algorithm and outline future directions for PG management.

Main Methods:

• Literature review of established and emerging treatments for PG.
• Analysis of pathogenic mechanisms driving treatment development.
• Synthesis of information to create a therapeutic algorithm.

Main Results:

• Systemic corticosteroids and cyclosporine are first-line treatments.
• Biologic therapies targeting TNF-α and IL-23 are effective in specific cases.
• JAK-STAT inhibitors demonstrate promising results for PG treatment.

Conclusions:

• Treatment of PG is evolving with a deeper understanding of its pathogenesis.
• Biologic and small molecule therapies offer new avenues for managing PG.
• A pathogenesis-driven approach is crucial for optimizing PG treatment strategies.